Skip to main content
SpringerLink
Log in

Monoclonal Antibodies in the Treatment of Malignant Lymphomas

  • Chapter
Targeted Therapies in Cancer

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 610))

Non-Hodgkin's lymphoma is a heterogeneous group of B- and T-cell cancers, with a large variety of patterns of growth, clinical presentations, and responses to treatment. Outcome depends on histological subtype, tumor characteristics, host responses, and treatment. About 90 percent of lymphomas have a B-cell phenotype and for them recent therapeutic progress came from the introduction of monoclonal antibodies (MAb) alone or in combination with chemotherapy (Coiffier 2005; Coiffier 2005; Traulle and Coiffier 2005). The first antigen that has been targeted for therapeutic purpose with success was the CD20 antigen, a transmembrane protein expressed by more than 99 percent of B-cell lymphomas. Rituximab was the first MAb engineered to target the CD20 antigen and first approved MAb for the treatment of lymphoma patients. Through the last 10 years clinical trials with rituximab have confirmed its efficacy in follicular lymphoma, as well as in aggressive lymphomas, and its use has expanded significantly beyond the initial indication of indolent B-cell lymphomas to virtually any CD20-positive lymphoma. In recent years, several other MAb targeting CD20 or other lymphocyte antigens appeared, some of them associated with a toxin or a radioisotope.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Alas, S., Bonavida, B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001;61:5137–44.

    PubMed  CAS  Google Scholar 

  • Alas, S., Bonavida, B., Emmanouilides, C. Potentiation of fludarabine cytotoxicity on non-Hodgkin’s lymphoma by pentoxifylline and Rituximab. Anticancer Res. 2000;20:2961–6.

    PubMed  CAS  Google Scholar 

  • Ardeshna, K. M., Smith, P., Norton, A., Hancock, B. W., Hoskin, P. J., MacLennan, K. A., Marcus, R. E., Jelliffe, A., Hudson, G. V., Linch, D. C. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin’s lymphoma: a randomised controlled trial. Lancet. 2003;362:516–22.

    Article  PubMed  CAS  Google Scholar 

  • Belhadj, K., Delfau-Larue, M. H., Elgnaoui, T., Beaujean, F., Beaumont, J. L., Pautas, C., Gaillard, I., Kirova, Y., Allain, A., Gaulard, P., Farcet, J. P., Reyes, F., Haioun, C. Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin’s lymphoma: a single institution study. Ann Oncol. 2004;15:504–10.

    Article  PubMed  CAS  Google Scholar 

  • Berinstein, N. L., Grillolopez, A. J., White, C. A., Bencebruckler, I., Maloney, D., Czuczman, M., Green, D., Rosenberg, J., McLaughlin, P., Shen, D. Association of serum rituximab (IDECC2B8) concentration and antitumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma. Ann Oncol. 1998;9:995–1001.

    Article  PubMed  CAS  Google Scholar 

  • Bienvenu, J., Chvetzoff, R., Salles, G., Balter, C., Tilly, H., Herbrecht, R., Morel, P., Lederlin, P., Solal-Celigny, P., Audhuy, B., Christian, B., Gabarre, J., Casasnovas, O., Marit, G., Sebban, C., Coiffier, B. Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J. 2001;2:378–84.

    Article  PubMed  CAS  Google Scholar 

  • Blaes, A. H., Peterson, B. A., Bartlett, N., Dunn, D. L., Morrison, V. A. Rituximab therapy is effective for post-transplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial. Cancer. 2005;104:1661–7.

    Article  PubMed  CAS  Google Scholar 

  • Boettcher, S., Pott, C., Ritgen, M., Hiddemann, W., Unterhalt, M., Kneba, M. Evidence for Fcγ receptor IIIA-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immuno-chemotherapy. In: Blood, editor. ASH 2004; 2004: Blood; 2004. p. 170a.

    Google Scholar 

  • Bohen, S. P., Troyanskaya, O. G., Alter, O., Warnke, R., Botstein, D., Brown, P. O., Levy, R. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Nat Acad Sci USA. 2003;100:1926–30.

    Article  PubMed  CAS  Google Scholar 

  • Boue, F., Gabarre, J., Gisselbrecht, C., Reynes, J., Cheret, A., Bonnet, F., Billaud, E., Raphael, M., Lancar, R., Costagliola, D. Phase II trial of CHOP plus rituximab in patients with HIVassociated non-Hodgkin’s lymphoma. J Clin Oncol. 2006;24:4123–8.

    Article  PubMed  CAS  Google Scholar 

  • Byrd, J. C., Murphy, T., Howard, R. S., Lucas, M. S., Goodrich, A., Park, K., Pearson, M., Waselenko, J. K., Ling, G., Grever, M. R., Grillo-Lopez, A. J., Rosenberg, J., Kunkel, L., Flinn, I. W. Rituximab using a thrice-weekly dosing schedule in B-Cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol. 2001;19:2153–64.

    PubMed  CAS  Google Scholar 

  • Byrd, J. C., Peterson, B. L., Morrison, V. A., Park, K., Jacobson, R., Hoke, E., Vardiman, J. W., Rai, K., Schiffer, C. A., Larson, R. A. Randomized phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6–14.

    Article  PubMed  CAS  Google Scholar 

  • Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., Watier, H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fc gamma RIIIa gene. Blood. 2002;99:754–8.

    Article  PubMed  CAS  Google Scholar 

  • Cartron, G., Watier, H., Golay, J., Solal-Celigny, P. From the bench to the bedside: ways to improve rituximab efficacy. Blood. 2004;104:2635–42.

    Article  PubMed  CAS  Google Scholar 

  • Cheson, B. D. Radioimmunotherapy of non-Hodgkin’s Lymphomas. Blood. 2003;101:391–8.

    Article  PubMed  CAS  Google Scholar 

  • Coiffier, B. Current strategies for the treatment of diffuse large B-cell lymphoma. Cur Op Hematol. 2005;12:In press.

    Google Scholar 

  • Coiffier, B. First-line treatment of follicular lymphoma in the era of monoclonal antibodies. Clin Adv Hematol Oncol. 2005;3:484–91.

    PubMed  Google Scholar 

  • Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van den Neste, E., Salles, G., Gaulard, P., Reyes, F., Gisselbrecht, C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.

    Article  PubMed  CAS  Google Scholar 

  • Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubeyran, P., Delwail, V., Deconinck, E., Haioun, C., Foussard, C., Sebban, C., Stamatoullas, A., Milpied, N., Boue, F., Taillan, B., Lederlin, P., Najman, A., Thieblemont, C., Montestruc, F., Mathieu-Boue, A., Benzohra, A., Solal-Celigny, P. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood. 2001;97:101–6.

    Article  PubMed  CAS  Google Scholar 

  • Conconi, A., Martinelli, G., Thieblemont, C., Ferreri, A. J. M., Devizzi, L., Peccatori, F., Ponzoni, M., Pedrinis, E., Dell’Oro, S., Pruneri, G., Filipazzi, V., Dietrich, P. Y., Gianni, A. M., Coiffier, B., Cavalli, F., Zucca, E. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741–5.

    Article  PubMed  CAS  Google Scholar 

  • Czuczman, M. S., Weaver, R., Alkuzweny, B., Berlfein, J., Grillo-Lopez, A. J. Prolonged Clinical and Molecular Remission in Patients With Low-Grade or Follicular Non-Hodgkin’s Lymphoma Treated With Rituximab Plus CHOP Chemotherapy: 9-Year Follow-Up. J Clin Oncol. 2005;23:DOI:10.1200/JCO.2004.04.020.

    Google Scholar 

  • Davis, T. A., Grillo-Lopez, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., Maloney, D. G., Weaver, R. L., Rosenberg, J., Levy, R. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin’s lymphoma: Safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135–43.

    PubMed  CAS  Google Scholar 

  • Demidem, A., Lam, T., Alas, S., Hariharan, K., Hanna, N., Bonavida, B. Chimeric Anti-Cd20 (Idec-C2b8) Monoclonal Antibody Sensitizes a B-Cell Lymphoma Cell Line to Cell Killing By Cytotoxic Drugs. Cancer Bioth Radiopharm. 1997;12:177–86.

    Article  CAS  Google Scholar 

  • Dillman, R. O. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell Lymphoma. Journal of clinical oncology. 2002;20:3545–57.

    Article  PubMed  CAS  Google Scholar 

  • Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A. P., Repp, R., Schetelig, J., Seipelt, G., Osterborg, A., Lundin, J., Kimby, E., Bjorkholm, M., Broliden, P. A., Celsing, F., Hjalmar, V., Mollgard, L., Rebello, P., Hale, G., Waldmann, H., Mellstedt, H., Osterborg, A. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.

    Google Scholar 

  • Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood. 2004;103:2920–4.

    Google Scholar 

  • Feugier, P., Van Hoof, A., Sebban, C., Solal-Celigny, P., Bouabdallah, R., Ferme, C., Christian, B., Lepage, E., Tilly, H., Morschhauser, F., Gaulard, P., Salles, G., Bosly, A., Gisselbrecht, C., Reyes, F., Coiffier, B. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l¢Adulte. J Clin Oncol. 2005;23:4117–26.

    Article  PubMed  CAS  Google Scholar 

  • Foran, J. M., Rohatiner, A. Z. S., Cunningham, D., Popescu, R. A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P. W. M., Gisselbrecht, C., Reyes, F., Radford, J. A., Bessell, E. M., Souleau, B., Benzohra, A., Lister, T. A. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol. 2000;18:317–24.

    PubMed  CAS  Google Scholar 

  • Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Haenel, A., Metzner, B., Pott, C., Hartmann, F., Rothmann, F., Rohrberg, R., Boeck, H. P., Wandt, H., Unterhalt, M., Hiddemann, W. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas -results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood. 2004;104:3064–71.

    Article  PubMed  CAS  Google Scholar 

  • Forstpointner, R., Unterhalt, M., Dreyling, M., Bock, H. P., Repp, R., Wandt, H., Pott, C., Seymour, J. F., Metzner, B., Hanel, A., Lehmann, T., Hartmann, F., Einsele, H., Hiddemann, W. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood. 2006;DOI: 10.1182/blood-2006–04–016725.

    Google Scholar 

  • Foussard, C., Mounier, N., Van Hoof, A., Delwail, V., Casasnovas, O., Deconinck, E., Tilly, H., Fitoussi, O., Gressin, R., Salles, G. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol. 2006;24.

    Google Scholar 

  • Ghetie, M. A., Bright, H., Vitetta, E. S. Homodimers. but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood. 2001;97:1392–8.

    Article  PubMed  CAS  Google Scholar 

  • Ghetie, M. A., Crank, M., Kufert, S., Pop, I., Vitetta, E. Rituximab, but not other anti-CD20 antibodies reverses multidrug resistance in 2 B lymphoma cell lines, blocks the activity of P- glycoprotein (P-gp), and induces P-gp to translocate out of lipid rafts. J Immunother. 2006;29:536–44.

    Article  PubMed  CAS  Google Scholar 

  • Ghielmini, M., Schmitz, S. F., Cogliatti, S. B., Pichert, G., Hummerjohann, J., Waltzer, U., Fey, M. F., Betticher, D. C., Martinelli, G., Peccatori, F., Hess, U., Zucca, E., Stupp, R., Kovacsovics, T., Helg, C., Lohri, A., Bargetzi, M., Vorobiof, D., Cerny, T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood. 2004;103:4416–23.

    Article  PubMed  CAS  Google Scholar 

  • Gianni, A. M., Magni, M., Martelli, M., Di Nicola, M., Carlo-Stella, C., Pilotti, S., Rambaldi, A., Cortelazzo, S., Patti, C., Parvis, G., Benedetti, F., Capria, S., Corradini, P., Tarella, C., Barbui, T. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood. 2003;102:749–55.

    Article  PubMed  CAS  Google Scholar 

  • Grillo-Lopez, A. J., Hedrick, E., Rashford, M., Benyunes, M. Rituximab: Ongoing and future clinical development. Sem Oncol. 2002;29:105–12.

    Article  CAS  Google Scholar 

  • Habermann, T. M., Weller, E. A., Morrison, V. A., Gascoyne, R. D., Cassileth, P. A., Cohn, J. B., Dakhil, S. R., Woda, B., Fisher, R. I., Peterson, B. A., Horning, S. J. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–7.

    Article  PubMed  CAS  Google Scholar 

  • Hagberg, H., Gisselbrecht, C. Randomized phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomization to maintenance treatment with rituximab or not: an update of the CORAL study. Ann Oncol. 2006;17 Suppl 4:iv31–2.

    Article  PubMed  Google Scholar 

  • Hainsworth, J. D., Litchy, S., Barton, J. H., Houston, G. A., Hermann, R. C., Bradof, J. E., Greco, F. A. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2003;21:1746–51.

    Article  PubMed  CAS  Google Scholar 

  • Hainsworth, J. D., Litchy, S., Burris, H. A., Scullin, D. C., Corso, S. W., Yardley, D. A., Morrissey, L., Greco, F. A. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:4261–7.

    Article  PubMed  CAS  Google Scholar 

  • Hainsworth, J. D., Litchy, S., Shaffer, D. W., Lackey, V. L., Grimaldi, M., Greco, F. A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin’s lymphoma–a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1088–95.

    Article  PubMed  CAS  Google Scholar 

  • Herold, M., et al. Results of a prospective randomized open label phase III study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. In:Blood, editor. ASH; 2004; San Diego: Blood; 2004. p. 169a.

    Google Scholar 

  • Hiddemann, W., Dreyling, M. H., Forstpointner, R., Kneba, M., Woermann, B., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Schmitz, N., Truemper, L., Eimermacher, H., Parwaresch, R. Combined Immuno-Chemotherapy (R-CHOP) Significantly Improves Time To Treatment Failure in First Line Therapy of Follicular Lymphoma Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG). In: Blood, editor. American Society of Hematology; 2003; San Diego, CA: Blood; 2003. p. 104a.

    Google Scholar 

  • Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H. E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R., Unterhalt, M. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–32.

    Article  PubMed  CAS  Google Scholar 

  • Hochster, H. S., Weller, E., Ryan, T., Habermann, T. M., Gascoyne, R., Frankel, S. R., Horning, S. J. Results of E1496: A phase III trial of CVP with or without maintenance with rituximab in advanced indolent lymphoma. In: ASCO P, editor. ASCO; 2004; New Orleans, LA: Proc ASCO; 2004. p. 556.

    Google Scholar 

  • Horwitz, S. M., Horning, S. J. Rituximab in stem cell transplantation for aggressive lymphoma. Curr Hematol Rep. 2004;3:227–9.

    PubMed  Google Scholar 

  • Jain, A. B., Marcos, A., Pokharna, R., Shapiro, R., Fontes, P. A., Marsh, W., Mohanka, R., Fung, J. J. Rituximab (Chimeric Anti-CD20 Antibody) for Posttransplant Lymphoproliferative Disorder after Solid Organ Transplantation in Adults: Long-Term Experience from a Single Center. Transplantation. 2005;80:1692–8.

    Article  PubMed  CAS  Google Scholar 

  • Janas, E., Priest, R., Wilde, J. I., White, J. H., Malhotra, R. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clin Exp Immunol. 2005;139:439–46.

    Article  PubMed  CAS  Google Scholar 

  • Juweid, M. E. Radioimmunotherapy of B-Cell Non-Hodgkin’s lymphoma: From clinical trials to clinical practice. Journal of Nuclear Medecine. 2002;43:1507–29.

    CAS  Google Scholar 

  • Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., Wahl, R. L. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–9.

    Article  PubMed  CAS  Google Scholar 

  • Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, A. T., Staag, R. J., Tidmarsh, G. F., Kroll, S., Walh, R. L., Knox, S. J., Vose, J. M. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphoma. Journal of clinical oncology. 2001;19:3918–28.

    PubMed  CAS  Google Scholar 

  • Kaplan, L. D., Scadden, D. T. for the AIDS Malignancies Consortium. No benefit from rituximab in a randomized phase III trial of CHOP with or without rituximab for patients with HIVassociated non-Hodgkin’s lymphoma: AIDS malignancies consortium study 010. In: Oncol PASC, editor. ASCO; 2004: Proc Am Soc Clin Oncol 2004. p. 564.

    Google Scholar 

  • Keating, M. J., Flinn, I., Jain, V., Binet, J. L., Hillmen, P., Byrd, J., Albitar, M., Brettman, L., Santabarbara, P., Wacker, B., Rai, K. R. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–61.

    Article  PubMed  CAS  Google Scholar 

  • Keating, M. J., O’Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., Andreeff, M., Cortes, J., Faderl, S., Thomas, D., Koller, C., Wierda, W., Detry, M. A., Lynn, A., Kantarjian, H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079–88.

    Article  PubMed  CAS  Google Scholar 

  • Kennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., Taylor, R. P. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia. J Immunol. 2004;172:3280–8.

    PubMed  CAS  Google Scholar 

  • Kim, D. H., Jung, H. D., Kim, J. G., Lee, J. J., Yang, D. H., Park, Y. H., Do, Y. R., Shin, H. J., Kim, M. K., Hyun, M. S., Sohn, S. K. FcGRIIIa gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006;108:2720–5.

    Article  PubMed  CAS  Google Scholar 

  • Kimby, E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31:456–73.

    Article  PubMed  CAS  Google Scholar 

  • Lemieux, B., Bouafia, F., Thieblemont, C., Hequet, O., Arnaud, P., Tartas, S., Traulle, C., Salles, G., Coiffier, B. Second treatment with rituximab in B-cell non-Hodgkin’s lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. Hematol J. 2004;In press.

    Google Scholar 

  • Lemieux, B., Coiffier, B. Radio-immunotherapy in low-grade non-Hodgkin’s lymphoma Best Practice & Research Clinical Haematology 2005;18:81–95.

    Google Scholar 

  • Lemieux, B., Tartas, S., Traulle, C., Espinouse, D., Thieblemont, C., Bouafia, F., Alhusein, Q., Antal D., Salles, G., Coiffier, B. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2004;33:921–3.

    Article  PubMed  CAS  Google Scholar 

  • Lim, S. H., Zhang, Y., Wang, Z., Esler, W. V., Beggs, D., Pruitt. B., Hancock, P., Townsend, M. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. Bone Marrow Transplant. 2005;35:207–8.

    Article  PubMed  CAS  Google Scholar 

  • Lim, S. H., Zhang, Y., Wang, Z., Esler, W. V., Beggs, D., Pruitt, B., Hancock, P., Townsend, M. Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia. 46th meeting of the American Socity of Hematology; 2004; San Diego, CA: Blood; 2004. p. 395a.

    Google Scholar 

  • Lundin, J., Hagberg, H., Repp, R., Cavallin-Stahl, E., Freden, S., Juliusson, G., Rosenblad, E., Tjonnfjord, G., Wiklund, T., Osterborg, A. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101:4267–72.

    Article  PubMed  CAS  Google Scholar 

  • Maloney, D. G. Preclinical and phase I and II trials of rituximab. Sem Oncol. 1999;26:74–8.

    CAS  Google Scholar 

  • Marcus, R., Imrie, K., Belch, A., Cunningham, D, Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A., Smith, P. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417–23.

    Article  PubMed  CAS  Google Scholar 

  • Marcus, R., Solal-Celigny, P., Imrie, K., Catalano, J., Dmoszynska, A., Raposo, J., Offner, F., Gomez-Codina, J. MabThera (Rituximab) Plus Cyclophosphamide, Vincristine and Prednisone (CVP) Chemotherapy Improves Survival in Previously Untreated Patients with Advanced Follicular Non-Hodgkins Lymphoma (NHL). Blood. 2006;108:.

    Google Scholar 

  • McLaughlin, P., Grillolopez, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bencebruckler, I., White, C. A., Cabanillas, F., Jain, V., Ho, A. D., Lister, J., Wey, K., Shen, D., Dallaire, B. K. Rituximab Chimeric Anti-Cd20 Monoclonal Antibody Therapy For Relapsed Indolent Lymphoma - Half of Patients Respond to a Four-Dose Treatment Program. J Clin Oncol. 1998;16:2825–33.

    PubMed  CAS  Google Scholar 

  • Milpied, N., Vasseur, B., Parquet, N., Garnier, J. L., Antoine, C., Quartier, P., Carret, A. S., Bouscary, D., Faye, A., Bourbigot, B., Reguerre, Y., Stoppa, A. M., Bourquard, P., de Ligny, B. H., Dubief, F., Mathieu-Boue, A., Leblond, V. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: A retrospective analysis on 32 patients. Ann Oncol. 2000;11:113–6.

    Article  PubMed  Google Scholar 

  • Neumann, F., Harmsen, S., Martin, S., Kronenwett, R., Kondakci, M., Aivado, M., Germing, U., Haas, R., Kobbe, G. Rituximab long-term maintenance therapy after autologous stem cell transplantation in patients with B-cell non-Hodgkin’s lymphoma. Ann Hematol. 2006;85:530–4.

    Article  PubMed  CAS  Google Scholar 

  • O’Brien, S. M., Kantarjian, H., Thomas, D. A., Giles, F. J., Freireich, E. J., Cortes, J., Lerner, S., Keating, M. J. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165–70.

    PubMed  Google Scholar 

  • Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., Oseroff, A., Pinter-Brown, L., Bowen, G., Kuzel, T., Fivenson, D., Foss, F., Glode, M., Molina, A., Knobler, E., Stewart, S., Cooper, K., Stevens, S., Craig, F., Reuben, J., Bacha, P., et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Journal of Clinical Oncology. 2001;19:376–88.

    PubMed  CAS  Google Scholar 

  • Pfreundschuh, M., Trumper, L., Osterborg, A., Pettengell, R., Trneny, M., Imrie, K., Ma, D., Gill, D., Walewski, J., Zinzani, P. L., Stahel, R., Kvaloy, S., Shpilberg, O., Jaeger, U., Hansen, M., Lehtinen, T., Lopez-Guillermo, A., Corrado, C., Scheliga, A., Milpied, N., Mendila, M., Rashford, M., Kuhnt, E., Loeffler M. CHOP-like chemotherapy plus rituximab versus CHOPlike chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.

    Article  PubMed  CAS  Google Scholar 

  • Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Nelp, W. B., Glenn, S., Fisher, D. R., Porter, B., Matthews, D. C., Gooley, T., Bernstein, I. D. Phase II trial of 131I–B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet. 1995;346:336–40.

    Article  PubMed  CAS  Google Scholar 

  • Press, O. W., Eary, J. F., Gooley, T., Gopal, A. K., Liu, S., Rajendran, J. G., Maloney, D. G., Petersdorf, S., Bush, S. A., Durack, L. D., Martin, P. J., Fisher, D. R., Wood, B., Borrow, J. W., Porter, B., Smith, J. P., Matthews, D. C., Appelbaum, F. R., Bernstein, I. D. A Phase I/II trial of iodine-131-tositumomab (anti CD-20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood. 2000;96:2934–42.

    PubMed  CAS  Google Scholar 

  • Press, O. W., Unger, J. M., Braziel, R. M., Maloney, D. G., Miller, T. P., Leblanc, M., Gaynor, E. R., Rivkin, S. E., Fisher, R. I. A Phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin ymphoma: Southwest Oncology Group Protocol S9911. Blood. 2003;102:1606–12.

    Article  PubMed  CAS  Google Scholar 

  • Rosenblum, M. Immunotoxins and toxin constructs in the treatment of leukemia and lymphoma. Adv Pharmacol. 2004;51:209–28.

    Article  PubMed  CAS  Google Scholar 

  • Salles, G., Foussard, C., Mounier, N., Morschhauser, F., Bosly, A., Lamy, T., Haioun, C., Brice, P., Boubadallah, R., Rossi, J-F, Audhuy, B., Fermé, C., Mahe, B., Lederlin, P., Sebban, C., Colombat, P., Xerri, L. Rituximab added to CHVP+IFN improves the outcome of follicular lymphoma patients: first analysis of the GELA-GOELAMS FL-2000 randomized trial. In:Blood, editor. ASH; 2004; San Diego: Blood; 2004. p. 49a.

    Google Scholar 

  • Smith, M. R. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359–68.

    Article  PubMed  CAS  Google Scholar 

  • Traulle, C., Coiffier, B. B. Evolving role of rituximab in the treatment of patients with non-Hodgkin’s lymphoma. Future Oncol. 2005;1:297–306.

    Article  PubMed  CAS  Google Scholar 

  • van Oers, M., Klasa, R., Marcus, R. E., Wolf, M., Kimby, E., Gascoyne, R. D., Jack, A., Veer, Mvt, Vranovsky, A., Holte, H., Glabbeke, Mv., Teodorovic, I., Rozewicz, C., Hagenbeek, A. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin’s lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–301.

    Article  PubMed  Google Scholar 

  • Vega, M. I., Huerta-Yepaz, S., Garban, H., Jazirehi, A., Emmanouilides, C., Bonavida, B. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 2004;23:3530–40.

    Article  PubMed  CAS  Google Scholar 

  • Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R. J., Kaminski, M.S. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas. Journal of clinical oncology. 2000;18:1316–23.

    PubMed  CAS  Google Scholar 

  • Weng, W. K., Levy, R. Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin’s lymphoma. Blood. 2001;98:1352–7.

    Article  PubMed  CAS  Google Scholar 

  • Weng, W. K., Levy, R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003;21:3940–7.

    Article  PubMed  CAS  Google Scholar 

  • Wierda, W., O’Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K. A., Cortes, J., Koller, C., Beran, M., Ferrajoli, A., Giles, F., Lerner, S., Albitar, M., Kantarjian, H., Keating, M. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4070–8.

    Article  PubMed  CAS  Google Scholar 

  • Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V., Engert, A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an Anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood. 1999;94:2217–24.

    PubMed  CAS  Google Scholar 

  • Witzig, T. E., Flinn, I. W., Gordon, L. I., Emmanouilides, C., Czuczman, M. S., Saleh, M. N., Cripe, L., Wiseman, G., Olejnik, T., Multani, P. S., White, C. A. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3262–9.

    Article  PubMed  CAS  Google Scholar 

  • Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., Grillo-Lopez, A. J., Multany, P., White, C. A. Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin’s Lymphoma. Journal of clinical oncology. 2002;20:2453–63.

    Article  PubMed  CAS  Google Scholar 

  • Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Spies, S., Silverman, D. H., Parker, E., Grillo-Lopez, A. J. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma. Journal of clinical oncology. 1999;17.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Department, Hospices Civils de Lyon and Claude Bernard University, CH Lyon-Sud, 69495, Pierre-Benite, France

    Bertrand Coiffier

Authors
  1. Bertrand Coiffier
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Nerviano Medical Sciences, 10 Viale Pasteur, Nerviano (Milano), 20014, Italy

    Francesco Colotta

  2. Istituto Clinico Humanitas and Institute of Pathology, University of Milan, 56 Via Manzoni, Rozzano, Milano, 20089, Italy

    Alberto Mantovani

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer

About this chapter

Cite this chapter

Coiffier, B. (2008). Monoclonal Antibodies in the Treatment of Malignant Lymphomas. In: Colotta, F., Mantovani, A. (eds) Targeted Therapies in Cancer. Advances in Experimental Medicine and Biology, vol 610. Springer, New York, NY. https://doi.org/10.1007/978-0-387-73898-7_12

Download citation

Publish with us

Policies and ethics

Search

Navigation